1-866-390-4411 info@x-gen.us

News

The Release of Dactinomycin for Injection, USP

Big Flats, NY., August 1st, 2019 – X-GEN Pharmaceuticals announced today the immediate availability in the United States of Dactinomycin for Injection, USP. Dactinomycin is an actinomycin indicated for the treatment of: • adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. • adult and pediatric patients with rhabdomyosarcoma, [...]

read more

X-GEN Pharmaceuticals Begins Marketing and Distributing Piperacillin and Tazobactam for Injection

Big Flats, NY, March 1, 2017 – X-GEN Pharmaceuticals announced today it will begin marketing and distributing Piperacillin and Tazobactam for Injection. X-GEN’s Piperacillin and Tazobactam for Injection is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for the treatment of various bacterial infections. The medical community has been plagued by shortages and inconsistencies in [...]

read more

X-GEN Pharmaceuticals and Exela Pharma Sciences Receive FDA Approval for Ibuprofen Lysine Injection

Big Flats, NY, May 2, 2016 – X-GEN Pharmaceuticals and Exela Pharma Sciences announced today that Exela Pharma Sciences’ ANDA for Ibuprofen Lysine Injection was approved by the FDA. X-GEN’s Ibuprofen Lysine Injection, under licensing agreement with Exela, is therapeutically equivalent to Recordati Rare Diseases’ NeoProfen® Injection and is the first available generic alternative in [...]

read more

X-GEN Pharmaceuticals receives first generic FDA approval for Lincomycin Injection, USP

Big Flats, NY, February 1, 2016 - X-GEN Pharmaceuticals, Inc. becomes the first generic alternative to receive FDA approval of their ANDA for the marketing and distribution of Lincomycin Injection, USP. Lincomycin is used to treat serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci when penicillin is inappropriate due to patient allergies [...]

read more

X-GEN Pharmaceuticals, Inc. Begins Supplying Magnesium Sulfate

Big Flats, NY, March 2, 2015 - X-GEN Pharmaceuticals announces availability of Magnesium Sulfate Injection, USP. Healthcare systems around the U.S are experiencing a shortage of Magnesium Sulfate, which is a critical component in Total Parenteral Nutrition (TPN), supplying vital nutrients to patients who need IV nutrition to stay alive. It also is indicated as [...]

read more

X-GEN Pharmaceuticals, Inc. Begins Marketing Nystatin Topical

Big Flats, NY, September 26, 2014 - X-GEN Pharmaceuticals, Inc. announced today that it is re-launching Nystatin Topical Powder USP, a generic product AT rated to Mycostatin®. Nystatin Topical Powder is an antibiotic used to treat skin infections caused by a wide variety of yeasts. X-GEN received FDA approval for Nystatin Topical in December of [...]

read more

X-GEN Pharmaceuticals and Exela Pharma Sciences Receive FDA Approval for Clonidine Hydrochloride Injection

Big Flats, NY – (February 17, 2014) - X-GEN Pharmaceuticals announced today FDA approval to begin marketing and distributing Clonidine Hydrochloride Injection as part of a development and licensing agreement with Exela Pharma Sciences. Exela Pharma Sciences developed and is the commercial manufacturer of the drug product. Clonidine is AP rated to Duraclon® and is [...]

read more

X-GEN Pharmaceuticals Receives FDA Approval for Tranexamic Acid

Big Flats, NY – (August, 2013) - X-GEN Pharmaceuticals, Inc. announces FDA approval to begin marketing and distributing Tranexamic Acid Injection. Tranexamic Acid is the generic product AP rated to Cyklokapron® and works by blocking the breakdown of blood clots in hemophiliacs. Tranexamic Acid reduces or prevents hemorrhage and can also minimize the potential need [...]

read more

MEDIA INQUERIES

X-GEN Pharmaceuticals, Inc.
300 Daniel Zenker Drive
Big Flats, NY 14814

+1 (866) 390-4411
info@x-gen.us

Archives